Cedar Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-356
Closed -$81.2K 90
2025
Q4
$81.2K Hold
356
0.02% 107
2025
Q3
$82.3K Buy
356
+1
+0.3% +$204 0.03% 110
2025
Q2
$66K Buy
355
+29
+9% +$5.39K 0.02% 107
2025
Q1
$68.3K Hold
326
0.02% 105
2024
Q4
$57.9K Sell
326
-665
-67% -$122K 0.02% 102
2024
Q3
$196K Hold
991
0.06% 105
2024
Q2
$170K Hold
991
0.06% 109
2024
Q1
$180K Buy
991
+65
+7% +$11.2K 0.06% 116
2023
Q4
$144K Sell
926
-100
-10% -$14.6K 0.05% 118
2023
Q3
$153K Hold
1,026
0.06% 116
2023
Q2
$138K Hold
1,026
0.05% 118
2023
Q1
$164K Sell
1,026
-432
-30% -$66K 0.07% 104
2022
Q4
$236K Sell
1,458
-108
-7% -$16.6K 0.12% 87
2022
Q3
$210K Sell
1,566
-54
-3% -$7.75K 0.1% 100
2022
Q2
$248K Hold
1,620
0.11% 94
2022
Q1
$263K Hold
1,620
0.11% 106
2021
Q4
$219K Sell
1,620
-42
-3% -$4.96K 0.09% 117
2021
Q3
$179K Hold
1,662
0.08% 111
2021
Q2
$187K Buy
1,662
+134
+9% +$15.1K 0.08% 109
2021
Q1
$165K Buy
1,528
+828
+118% +$88.6K 0.08% 105
2020
Q4
$75K Hold
700
0.04% 121
2020
Q3
$61K Hold
700
0.04% 121
2020
Q2
$69K Hold
700
0.05% 116
2020
Q1
$53K Buy
700
+100
+17% +$8.52K 0.04% 122
2019
Q4
$53K Hold
600
0.03% 88
2019
Q3
$45K Hold
600
0.03% 95
2019
Q2
$44K Buy
+600
New +$47.2K 0.03% 110
2017
Q3
Sell
-40
Closed -$3K 138
2017
Q2
$3K Hold
40
﹤0.01% 120
2017
Q1
$3K Hold
40
﹤0.01% 120
2016
Q4
$3K Hold
40
﹤0.01% 115
2016
Q3
$3K Hold
40
﹤0.01% 104
2016
Q2
$2K Sell
40
-80
-67% -$4.88K ﹤0.01% 116
2016
Q1
$7K Buy
+120
New +$6.69K ﹤0.01% 92

Other funds holding ABBV

Cedar Wealth Management's ABBV Position: Q1 2026 in Review

Cedar Wealth Management sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 356 shares — an estimated $81.2K sold.

Cedar Wealth Management first reported a position in ABBV in Q1 2016 and held it in 33 quarters. The position peaked at $263K in Q1 2022. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Cedar Wealth Management reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
  • Cedar Wealth Management sold 356 AbbVie shares in Q1 2026, an estimated $81.2K.
  • Cedar Wealth Management first reported a position in AbbVie in Q1 2016 and held it in 33 quarters.
  • Cedar Wealth Management's AbbVie position peaked at $263K in Q1 2022.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Cedar Wealth Management's 13F filing for Q1 2026, filed 14 May 2026.